Yonsei Med J.  2010 May;51(3):375-384. 10.3349/ymj.2010.51.3.375.

Association of Plasma Retinol-Binding Protein 4, Adiponectin, and High Molecular Weight Adiponectin with Insulin Resistance in Non-Diabetic Hypertensive Patients

• Shim CY
• Park S
• Kim JS
• Shin DJ
• Ko YG
• Kang SM
• Choi D
• Ha JW
• Jang Y
• Chung N

• KMID: 1074989
• DOI: http://doi.org/10.3349/ymj.2010.51.3.375

Abstract

PURPOSE
The aim of this study was to determine whether retinol-binding protein 4 (RBP4), adiponectin and high molecular weight (HMW) adiponectin are associated with insulin resistance (IR) and metabolic parameters in non-diabetic hypertensive patients. Also, we sought to compare the predictive values of these adipocytokines for IR in non-diabetic hypertensive patients.
MATERIALS AND METHODS
Analyses of RBP4, adiponectin, and HMW adiponectin were performed on 308 non-diabetic hypertensives (148 males, age 58 +/- 10 years, 189 non-metabolic syndrome and 119 metabolic syndrome). The homeostasis model assessment (HOMA) index for IR, lipid profiles, and anthropometric measure-ments were assessed.
RESULTS
There was no significant difference in RBP4 levels according to the presence of metabolic syndrome, although adiponectin and HMW adiponectin were significantly lower in metabolic syndrome. Correlation analysis of log RBP4 with IR and metabolic indices revealed that there was no significant correlation of RBP4 with waist circumference (r = 0.056, p = 0.324), HDL cholesterol (r = 0.005, p = 0.934), ApoB/ApoAI ratio (r = 0.066, p = 0.270), and the HOMA index (r = 0.017, p = 0.756). However, adiponectin and HMW adiponectin showed significant correlations with the HOMA index (r = - 0.247, p < 0.001; r = - 0.296, p < 0.001) and metabolic parameters. With IR defined as HOMA index > or = 2.5, HMW adiponectin did not demonstrate a superior predictive value for IR compared to adiponectin (AUC = 0.680 vs. 0.648, p = 0.083). The predictive value of RBP4 for IR was minimal (AUC = 0.534).
CONCLUSION
RBP4 was not associated with IR or metabolic indices and the predictive value for IR was minimal in hypertensives. HMW adiponectin didn't have a superior predictive value for IR compared to adiponectin. Therefore, we can suggest that RBP4 and HMW adiponectin don't have more additive information than adiponectin in non-diabetic hypertensives.

Keyword

Retinol-binding proteins; adiponectin; hypertension; insulin resistance

MeSH Terms

Adiponectin/*blood
Aged
Enzyme-Linked Immunosorbent Assay
Female
Humans
Hypertension/*blood/*physiopathology
Insulin Resistance/*physiology
Male
Middle Aged
Radioimmunoassay
Retinol-Binding Proteins, Plasma/*metabolism
Risk Factors
Waist Circumference/physiology

Figure

• 

  Fig. 1 Correlation of RBP4, adiponectin, and HMW adiponectin with metabolic parameters in hypertensive subjects. (A) Log RBP4, (B) Log adiponectin, (C) Log HMW adiponectin. RBP4, retinol-binding protein 4; HMW, high-molecular weight.

• 

  Fig. 2 ROC curves of adipocytokines for prediction of insulin resistance, defined as HOMA-IR index > 2.5 (n = 308), in hypertensive subjects. (A) Plasma adiponectin and HMW adiponectin. (B) Plasma RBP4. AUC, area under curve; ROC, receiver operating characteristics; HOMA, homeostasis model assessment; RBP4, retinol-binding protein 4.

Reference

1. Kannel WB. Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens. 2000. 13:3S–10S.

2. Ansell BJ. Evidence for a combined approach to the management of hypertension and dyslipidemia. Am J Hypertens. 2005. 18:1249–1257.

3. Wilson PW, Kannel WB, Silbershatz H, D'Agostino RB. Clustering of metabolic factors and coronary heart disease. Arch Intern Med. 1999. 159:1104–1109.

4. Thomas F, Rudnichi A, Bacri AM, Bean K, Guize L, Benetos A. Cardiovascular mortality in hypertensive men according to presence of associated risk factors. Hypertension. 2001. 37:1256–1261.

5. Adamczak M, Wiecek A, Funahashi T, Chudek J, Kokot F, Matsuzawa Y. Decreased plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens. 2003. 16:72–75.

6. Iwashima Y, Katsuya T, Ishikawa K, Ouchi N, Ohishi M, Sugimoto K, et al. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension. 2004. 43:1318–1323.

7. Baratta R, Amato S, Degano C, Farina MG, Patanè G, Vigneri R, et al. Adiponectin relationship with lipid metabolism is independent of body fat mass: evidence from both cross-sectional and intervention studies. J Clin Endocrinol Metab. 2004. 89:2665–2671.

8. Cnop M, Havel PJ, Utzschneider KM, Carr DB, Sinha MK, Boyko EJ, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia. 2003. 46:459–469.

9. Graham TE, Yang Q, Blüher M, Hammarstedt A, Ciaraldi TP, Henry RR, et al. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med. 2006. 354:2552–2563.

10. Lee DC, Lee JW, Im JA. Association of serum retinol binding protein 4 and insulin resistance in apparently healthy adolescents. Metabolism. 2007. 56:327–331.

11. Fisher FF, Trujillo ME, Hanif W, Barnett AH, McTernan PG, Scherer PE, et al. Serum high molecular weight complex of adiponectin correlates better with glucose intolerance than total serum adiponectin in Indo-Asian males. Diabetologia. 2005. 48:1084–1087.

12. Hara K, Horikoshi M, Yamauchi T, Yago H, Miyazaki O, Ebinuma H, et al. Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care. 2006. 29:1357–1362.

13. Janke J, Engeli S, Böhnke M, Adams F, Bhnke J, Luft FC, et al. Retinol binding protein 4 in human obesity. Diabetes. 2006. 55:2805–2810.

14. Broch M, Vendrell J, Ricart W, Richart C, Fernández-Real JM. Circulating retinol binding protein-4, insulin sensitivity, insulin secretion and insulin disposition index in obese and nonobese subjects. Diabetes Care. 2007. 30:1802–1806.

15. Tan CE, Ma S, Wai D, Chew SK, Tai ES. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians? Diabetes Care. 2004. 27:1182–1186.

16. Jungner I, Marcovina S, Walldius G, Holme I, Kolar W, Steiner E. Apolipoprotein B and A-I values in 147576 Swedish males and females, standardized according to the World Health Organization-International Federation of Clinical Chemistry First International Reference Materials. Clin Chem. 1998. 44:1641–1649.

17. Jungner I, Walldius G, Holme I, Kolar W, Steiner E. Apolipoprotein B and A-I in relation to serum cholesterol and triglyceride in 43,000 Swedish males and females. Int J Clin Lab Res. 1992. 21:247–255.

18. Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature. 2005. 436:356–362.

19. Takashima N, Tomoike H, Iwai N. Retinol-binding protein 4 and insulin resistance. N Engl J Med. 2006. 355:1392.

20. Tripathy D, Tuomi T, Almgren P, Groop L. Contribution of insulin-stimulated glucose uptake and basal hepatic insulin sensitivity to surrogate measures of insulin sensitivity. Diabetes Care. 2004. 27:2204–2210.

21. Stefan N, Hennige AM, Staiger H, Machann J, Schick F, Schleicher E, et al. High circulating retinol-binding protein 4 is associated with elevated liver fat but not with total, subcutaneous, visceral, or intramyocellular fat in humans. Diabetes Care. 2007. 30:1173–1178.

22. Bowles WH. Influence of insulin on liver vitamin A in rats. Diabetes. 1967. 16:704–707.

23. Sasaki H, Iwasaki T, Kato S, Tada N. High retinol/retinol-binding protein ratio in non insulin-dependent diabetes mellitus. Am J Med Sci. 1995. 310:177–182.

24. Lara-Castro C, Luo N, Wallace P, Klein RL, Garvey WT. Adiponectin multimeric complexes and the metabolic syndrome trait cluster. Diabetes. 2006. 55:249–259.

25. Blüher M, Brennan AM, Kelesidis T, Kratzsch J, Fasshauer M, Kralisch S, et al. Total and high-molecular weight adiponectin in relation to metabolic variables at baseline and in response to an exercise treatment program: comparative evaluation of three assays. Diabetes Care. 2007. 30:280–285.

26. Wang Y, Lam KS, Chan L, Chan KW, Lam JB, Lam MC, et al. Post-translational modification of the four conserved lysine residues within the collagenous domain of adiponectin are required for the formation of its high molecular weight oligomeric complex. J Biol Chem. 2006. 281:16391–16400.

27. Lee TS, Chang CC, Zhu Y, Shyy JY. Simvastatin induces heme oxygenase-1: a novel mechanism of vessel protection. Circulation. 2004. 110:1296–1302.

28. Li M, Kim DH, Tsenovoy PL, Peterson SJ, Rezzani R, Rodella LF, et al. Treatment of obese diabetic mice with a heme oxygenase inducer reduces visceral and subcutaneous adiposity, increases adiponectin levels, and improves insulin sensitivity and glucose tolerance. Diabetes. 2008. 57:1526–1535.

29. Nicolai A, Li M, Kim DH, Peterson SJ, Vanella L, Positano V, et al. Heme oxygenase-1 induction remodels adipose tissue and improves insulin sensitivity in obesity-induced diabetic rats. Hypertension. 2009. 53:508–515.